Protection against cisplatin nephrotoxicity by prochlorperazine.
Prochlorperazine (Compazine; PCPZ) is often used to limit cisplatin (CDDP)-induced emesis. However, recent studies in mice have shown that PCPZ protects against renal injury produced by treatment with various nephrotoxicants (e.g., MethylCCNU, mercuric chloride). Because renal toxicity remains a serious limitation to the effective use of CDDP, we conducted the present study to determine whether PCPZ could also protect against CDDP-induced renal injury. PCPZ treatment was shown to ameliorate CDDP-induced renal lesions in both rats and mice at doses and treatment schedules that were comparable with those used for alleviating chemotherapy-induced emesis. A PCPZ dose of 10 mg/kg x 2 offered complete protection against CDDP-induced increases in blood urea nitrogen (BUN) levels in mice, with significant protection occurring at a PCPZ dose as low as 5 mg/kg. Similarly, PCPZ ameliorated CDDP-induced increases in BUN, glucosouria, and enzymuria in F344 rats. PCPZ treatment did not affect the urinary excretion or renal tissue levels of total platinum or the plasma pharmacokinetics of free platinum. However, it did cause a marked reduction in the concentration of total plasma platinum (free platinum + protein-bound platinum). PCPZ was not found to affect the in vivo antitumor activity of CDDP against P388 leukemia. The present study suggests that PCPZ may be of therapeutic benefit when used with CDDP and provides a rational basis for the selection of antiemetic therapy.
Kramer
R A
RA
Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA 02115.
D000818:Animals; D002945:Cisplatin / Q000493:pharmacokinetics / Q000627:therapeutic use / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D007941:Leukemia P388 / Q000188:drug therapy / Q000401:mortality; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D011346:Prochlorperazine / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344; D013997:Time Factors
D002945:Cisplatin; D011346:Prochlorperazine